Acute Kidney Injury Stem Cell Therapy Development

Acute kidney injury (AKI), also called acute renal failure or acute renal failure, is a sudden decrease in the ability of the kidneys to work and perform their normal functions. CD BioSciences has launched a development service for AKI stem cell therapy, dedicated to advancing the treatment of this disease.

Overview of Acute Kidney Injury

The kidneys maintain homeostasis (Kellum, et al., 2021)

Acute Kidney Injury (AKI) is a sudden and rapid decline in kidney function. This condition occurs when the kidneys are unable to filter waste products and excess fluids from the blood effectively, leading to a buildup of harmful substances in the body. AKI can be caused by a variety of factors, including dehydration, low blood pressure, infections, medications, autoimmune diseases, and damage to the kidneys themselves. Symptoms may include decreased urine output, swelling, fatigue, confusion, and nausea.

Acute kidney injury (AKI) can affect almost all systems of the body in different ways. It affects the lungs and heart, often with clinical signs of respiratory or circulatory failure. And it also damages the gastrointestinal system, such as the liver or intestines, promoting intestinal barrier dysfunction and the translocation of bacteria and bacterial toxins.

Stem Cell Therapy for Acute Kidney Injury

The multiple functions of MSCs, including differentiation capacity, pro-angiogenic and immunomodulatory properties, make them ideal candidates for renal regenerative therapy. However, MSCs are barely detectable in the recovered tissue, which suggests that paracrine effects rather than MSC itself are responsible for tissue regeneration. What's more, MSCs treatment improves glomerular filtration, renal function, reduces oxidative stress-induced cellular senescence and inflammation, and increases renal cell proliferation.

Kidney regeneration by MSC-derived extracellular vesicles in acute kidney injury (Lee, et al., 2021)

MSCs facilitate renal regeneration by releasing paracrine factors and extracellular vesicles (EVs) to recipient kidney cells and are considered promising cellular therapies for AKI. EVs are derived from donor cells, lipid bilayer-separated particles (MPs), and work in a microenvironment to carry large amounts of proteins, lipids, messenger RNA (mRNA), microRNA (miRNA), long-stranded non-coding RNA (lncRNA), and other organelles from donor stem cells to recipient cells. Compared to MSCs themselves, MSC-derived EVs are smaller, cell-free, more stable, more biocompatible and less toxic. They are considered suitable as MSCs-based therapies.

Our Services

CD BioSciences offers stem cell therapy development services in acute kidney injury. Based on our professional laboratory team, we can contribute to the development of stem cell therapy for acute kidney injury.

Workflow of Our Service

As a pioneer in biotechnology, CD BioSciences has grown into one of the largest independent biotechnology companies in the world. CD BioSciences is committed to providing professional and efficient service to our customers around the world. If you are interested in our service, please contact us.

References

1. Kellum, J.A., Romagnani, P., Ashuntantang, G. et al. Acute kidney injury. Nat Rev Dis Primers 7, 52 (2021).
2. Lee, Pei-Wen et al. "Molecular Mechanisms of Mesenchymal Stem Cell-Based Therapy in Acute Kidney Injury." International journal of molecular sciences vol. 22,21 11406. 22 Oct. 2021.